Of note, TIL-TCRs expanded in response to chemo-immunotherapy could be identified within the same cluster expressing CX3CR1 at pretreatment in line with recent studies evaluating the tumor and a time-matched blood sample from patients with melanoma with scRNA/TCR-seq (21, 40). Here, CX3CR1 is linked to neoplasm.